Form 4: Recursion Pharmaceuticals CFO Ben R. Taylor Reports Acquisition of Restricted Stock Units and Stock Options
SEC Form 4 Filing
Chief Financial Officer of Recursion Pharmaceuticals, Ben R. Taylor, reports the acquisition of restricted stock units and stock options, along with adjustments to his holdings of Class A Common Stock.
Summary
- On December 19, 2024, Ben R. Taylor, the Chief Financial Officer of Recursion Pharmaceuticals, reported transactions involving the company's securities.
- Taylor acquired 370,343 shares of Class A Common Stock at $0, increasing his direct holdings to 844,210 shares.
- Taylor was also granted stock options for 740,686 shares of Class A Common Stock at an exercise price of $6.09, expiring on December 18, 2034.
- These options vest monthly starting January 2, 2025.
- Taylor also holds existing stock options with varying exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the CFO suggests confidence, but it's a routine transaction.
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The reported transactions indicate continued vesting of previously granted stock options and future vesting of newly granted restricted stock units and stock options, contingent on the executive's continued service.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The transactions could have a minor positive impact on shareholder sentiment, reflecting confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| 11/17/2021 | Twenty-five percent of the shares subject to the $0.04 stock option award vest and become exercisable. |
| 04/03/2022 | Twenty-five percent of the shares subject to the $0.06 stock option award vest and become exercisable. |
| 07/01/2022 | Twenty-five percent of the shares subject to the $0.14 stock option award vest and become exercisable. |
| 12/19/2024 | Date of the reported transactions: acquisition of restricted stock units and stock options. |
| 01/02/2025 | 1/48th of the shares subject to the $6.09 stock option award vests and become exercisable. |
| 02/15/2025 | 1/16th of the shares subject to the restricted stock units award vest. |
| 11/26/2030 | Expiration date for stock options with an exercise price of $0.04. |
| 04/02/2031 | Expiration date for stock options with an exercise price of $0.06. |
| 07/01/2031 | Expiration date for stock options with an exercise price of $0.14. |
| 12/18/2034 | Expiration date for stock options with an exercise price of $6.09. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.